Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Omidubicel is a first-in-class, advanced NAM (nicotinamide)-enabled stem cell therapy candidate.
Among nonresponders to initial COVID-19 vaccination, seroconversion occurred in 56 percent following booster dose
Stay up-to-date on the latest drugs in development.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
The approval was based on data from the phase 3 AGILE trial.
GPH101 is an investigational gene-edited autologous hematopoietic stem cell therapy designed to correct the mutation in the beta-globin gene and potentially curing the disease.
Women in academic medicine typically have lower starting salaries than men, and this disparity remains after 10 years on the job.